The COVID-19 vaccine rollout represented a relentless stress test for pharmaceutical supply chains, revealing both strengths and breaking points. The pandemic was a black swan event – a crisis few saw coming, yet one that reshaped our industry overnight. However, hindsight suggests warning signs were there. The real question is: are we now better prepared for whatever comes next?
I would argue that supply chains are more resilient than five years ago, but the risks we face have not disappeared.
Readiness does not just depend on stockpiling supplies or refining production timelines. It requires the strength of the partnerships that keep our supply chains moving – because manufacturers cannot succeed alone.
Strong partnerships across our supply chain, spanning logistics providers, container suppliers, and airlines, are what determine supply chain resilience in a crisis. These partnerships can improve operational efficiency, lower costs and provide access to specialized expertise. By aligning capabilities and resources, regulatory compliance and risk management is also strengthened, helping create a more agile, responsive and resilient supply chain. Those who invest in long-term relationships, treating logistics as a strategic function rather than a procurement challenge, will be the ones best positioned to adapt when disruption strikes.
The COVID-19 vaccine rollout proved this. The urgency of distribution forced the industry to create temporary high-volume supply chains, such as emergency routes from China to South America. Some of these were built on our pre-existing partnerships, but many had to be formed from scratch under immense pressure. Those with established relationships had a clear advantage, while those without them were left scrambling.
The key takeaway is clear to me. Logistics cannot be treated as a commodity service, bought and sold at the lowest possible rate. The next crisis will again favor those who invest in strong, multi-tiered partnerships that can be activated quickly when the pressure is on. After all, the most successful vaccine distributions were those where manufacturers, packaging solution providers, logistics providers, airlines, and even local handling teams worked together as a single unit.
Capacity as the weakest link
Securing enough space on planes to transport vaccines at the necessary scale and speed was a surprisingly difficult challenge during the vaccine airlift. Passenger aircraft, which typically handle a large share of global air cargo, were grounded, drastically shrinking freight capacity. The situation was only eased because demand for other pharmaceuticals temporarily dropped, freeing up space, but there is no guarantee that future crises will align in the same way, making rapid, large-scale distribution a continuing concern. Future geopolitical tensions or airline economics could also further reduce available freight space.
A lack of skilled workers further adds to the unpredictability. The logistics industry is facing shortages of pilots, warehouse staff, and trained handlers. Without the right personnel in place, even the best supply chain plans will fail. We must think beyond physical assets and invest in workforce development.
Many risks facing my pharma logistics today, including geopolitical tensions, trade restrictions, and sudden demand spikes, are just as disruptive as a pandemic. While future crises are impossible to predict, we must move from reactive crisis management to proactive scenario planning. Being caught unprepared is no longer an excuse.
During the pandemic, the companies that adapted best were agile, had access to data-driven insights, and had already built strong supply chain relationships. Future preparedness should focus on securing logistics capacity through strategic partnerships and pre-agreed contracts that guarantee access when demand spikes, rather than scrambling for space during an emergency.
It should also involve our industry building multi-source supply chain networks that are not dependent on a single provider or region. Investing in real-time monitoring and risk assessment tools will allow a company to track factors such as trade lane risks, shipment conditions and peak congestion periods, identifying potential disruptions before they become bottlenecks.
Companies should also put data to use in a meaningful way. Trade lane risk assessments, predictive analytics, and AI-driven forecasting will be the difference between a supply chain that bends under pressure and one that breaks entirely. The industry should work closely with logistics partners to integrate new technology and data-driven decision-making into supply chains before it is truly needed. The next crisis should be about more than just a willingness to adapt. We need real-time intelligence, flexible capacity planning and deep collaboration.
Collaboration is key
In the future, whether the next black swan event comes in the shape of another pandemic, geopolitical crisis, or extreme weather event, one thing is for certain: it will test the limits of our pharma supply chains again. Our success will not be defined just by how fast drugs can be manufactured but by whether the right partnerships are in place to move products effectively. And critically, whether those partnerships are strong enough to survive under pressure.
Pharma manufacturers, who integrate logistics planning into their long-term strategy, rather than treating it as an afterthought, will be among those who succeed in the next global crisis. The days of our industry treating logistics as a secondary concern are over. We all need to take an active role in ensuring my supply chains are resilient, adaptable, and ready for whatever comes next.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
